Hisamitsu Pharmaceutical Co., Inc. provided consolidated earnings guidance for the fiscal year ending February 29, 2024. For the period, the company expected net sales of JPY 141,000 million, operating profit of JPY 14,400 million, profit attributable to owners of parent of JPY 14,600 million and profit per share of JPY 188.85.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3,752 JPY | +0.94% | +1.30% | -12.97% |
06-24 | Hisamitsu Pharmaceutical Co., Inc.(TSE:4530) dropped from S&P Japan Mid Cap 100 | CI |
05-24 | Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on May 23, 2024. | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.97% | 1.69B | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+13.31% | 218B | |
+8.48% | 168B |
- Stock Market
- Equities
- 4530 Stock
- News Hisamitsu Pharmaceutical Co., Inc.
- Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024